CP009 SYNERGOSS PXX Observational

Sponsor
Nobil Bio Ricerche srl (Industry)
Overall Status
Unknown status
CT.gov ID
NCT02775058
Collaborator
(none)
22
1
35
0.6

Study Details

Study Description

Brief Summary

The device under investigation is SYNERGOSS, a CE (European Community CE) marked device.

Synergoss is a granulated bone graft intended for use in dental applications. It is composed of a ceramic composite of Hydroxihapatite and Tricalciumphosphate in granules, coated with a dedicated collagen coating (porcine origin), obtained by means of collagen crosslinking on the ceramic granule surface.

The purpose of the study is to confirm the foreseen efficacy and tolerability of SYNERGOSS, a synthetic dental graft coated with collagen. For this observational study, we will enroll patients that already received a surgical intervention for sinus augmentation/ socket preservation by means of SYNERGOSS to maintain and regenerate bone before installation of endosseous titanium implants to support a fixed prosthesis. Patients will be enrolled just before they receive the surgery for the installation of endosseous titanium implants, about 24 weeks after the first surgery for the implant of SYNERGOSS.

The primary hypothesis is to demonstrate that SYNERGOSS consistently obtains the foreseen clinical benefit as declared in the Technical File.

The secondary hypothesis is to demonstrate that SYNERGOSS side effects and risks match those declared in the Technical File.

The study design is a

  • National

  • Monocentric

  • Prospective: the participants are identified and then followed forward in time.

  • Observational: participants that have recently received the grafting with SYNERGIES as part of normal and foreseen clinical procedures are enrolled in the study when they receive surgery for titanium implant placement and observed over time, with no substantial intervention other than the foreseen clinical treatment

Condition or Disease Intervention/Treatment Phase
  • Device: synergoss Pxx

Study Design

Study Type:
Observational
Anticipated Enrollment :
22 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Clinical Evaluation Protocol Post Market Follow Up Pavia CP009 SYNERGOSS PXX Observational
Study Start Date :
Jun 1, 2016
Anticipated Primary Completion Date :
May 1, 2017
Anticipated Study Completion Date :
May 1, 2019

Arms and Interventions

Arm Intervention/Treatment
patients

The subjects enrolled in this CI just received dental grafting by the device under evaluation and in any case will be subject to the same procedures foreseen for this CI for the dental implant surgery.

Device: synergoss Pxx
dental grafting

Outcome Measures

Primary Outcome Measures

  1. • Bone Volume total (%BV) [4-6 months]

    The specimen, extracted from the bone of the patient, will be evaluated to define the quantity of total bone volume as compared to the specimen volume

  2. • graft Volume (%graft) [4-6 months]

    The specimen, extracted from the bone of the patient, will be evaluated to define the quantity of residual, non absorbed graft volume as compared to the specimen volume

  3. • vital bone (%VB). [4-6 months]

    The specimen, extracted from the bone of the patient, will be evaluated to define the quantity of vital, new formed bone volume as compared to the specimen volume

  4. • device radiologic density (in a qualitative scale ranging from 1 to 4) [4-6 months]

    the radiological density is visually evaluated by the investigator

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • • Received in the past 16-24 weeks a bone graft for sinus lift or socket preservation with the ID

  • Capable of giving a valid informed consent

  • ASA 1, ASA 2

  • agrees to return for follow-up visits up to 2 years

Exclusion Criteria:
  • • Uncontrolled Diabetes

  • Patients with psychiatric diseases

  • Neoplasic, immunodepressive, renal or liver major illnesses

  • Local radiotherapy

  • Major bruxism or major differences in the maxilla or mandubilar area

  • Drug or alcohol abuse

  • Major bone metabolism disorders

  • Heavy smokers (more than 10/day)

  • bisphosphonate treatment of major ostheoporosys or bone neoplasia

  • Pregnant women

  • Sinus illnesses

  • Contraindications to implant supported prostheses

  • Patients ASA 3,ASA 4, ASA5

  • Surgical intervention contraindications

Contacts and Locations

Locations

Site City State Country Postal Code
1 Policlinico S. Matteo - Pavia Pavia PV Italy 27100

Sponsors and Collaborators

  • Nobil Bio Ricerche srl

Investigators

  • Principal Investigator: Ruggero Rodriguez y Baena, POLICLINICO S. MATTEO - PAVIA

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Nobil Bio Ricerche srl
ClinicalTrials.gov Identifier:
NCT02775058
Other Study ID Numbers:
  • CP009
First Posted:
May 17, 2016
Last Update Posted:
Jun 29, 2016
Last Verified:
Jun 1, 2016
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 29, 2016